Limits...
Comparison of treatment adherence between selective serotonin reuptake inhibitors and moclobemide in patients with social anxiety disorder.

Lim SW, Kwon YS, Ha J, Yoon HG, Bae SM, Shin DW, Shin YC, Oh KS - Psychiatry Investig (2012)

Bottom Line: Overall, all-cause discontinuation rates were significantly lower with SSRIs (81%) than moclobemide (96%, χ²=4.532, p=0.033).The SSRI group had a longer treatment duration and lower all-cause discontinuation rate than moclobemide.Further, only the type of medication had a significant effect on all-cause discontinuation rates and therefore, we could predict better treatment adherence with the SSRIs in the treatment of SAD.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

ABSTRACT

Objective: With respect to the pharmacotherapy of social anxiety disorder (SAD), it has been suggested that treatment duration is an important factor that can significantly predict responses. The present study aimed to compare the treatment adherence of SAD patients who were taking either SSRIs or reversible inhibitors of MAO-A (moclobemide) by measuring treatment duration and all-cause discontinuation rates of pharmacotherapy in a natural clinical setting.

Methods: We retrospectively analysed the data of 172 patients diagnosed with SAD. Depending on their medication, we divided the patients into two groups, SSRI (n=54) or moclobemide (n=118). The expected number of all-cause discontinuation every 2 weeks after starting treatment was calculated by life table survival methods. A multi-variable Cox proportional hazard regression was used to analyze the potential influence of explanatory variables.

Results: Treatment duration was significantly longer in the SSRI group [46.41±56.96, median=12.0 (weeks)] than in the moclobemide group [25.53±34.74, median=12.0 (weeks), Z=2.352, p=0.019]. Overall, all-cause discontinuation rates were significantly lower with SSRIs (81%) than moclobemide (96%, χ²=4.532, p=0.033).

Conclusion: The SSRI group had a longer treatment duration and lower all-cause discontinuation rate than moclobemide. Further, only the type of medication had a significant effect on all-cause discontinuation rates and therefore, we could predict better treatment adherence with the SSRIs in the treatment of SAD.

No MeSH data available.


Related in: MedlinePlus

Proportion of patients without all-cause discontinuation over the treatment course in the SSRI and Moclobemide groupsSSRI: Selective Serotonin Reuptake Inhibitor.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3285744&req=5

Figure 1: Proportion of patients without all-cause discontinuation over the treatment course in the SSRI and Moclobemide groupsSSRI: Selective Serotonin Reuptake Inhibitor.

Mentions: In order to compare the observed number of all-cause discontinuation with what would be expected between the SSRI and moclobemide groups, the expected number of all-cause discontinuation every 2 weeks after starting medication was calculated under the assumption that each patient's risk of discontinuation would be equal to the risk of the general population. To analyse this risk, life table survival methods were used.28 Life table survival curves were generated to quantify the time to each medication discontinuation or switching, and to compare the survival curves between two medication groups during the total treatment period after starting medications. Differences in survival curves for both groups were compared using the Wilcoxon statistic (Figure 1).


Comparison of treatment adherence between selective serotonin reuptake inhibitors and moclobemide in patients with social anxiety disorder.

Lim SW, Kwon YS, Ha J, Yoon HG, Bae SM, Shin DW, Shin YC, Oh KS - Psychiatry Investig (2012)

Proportion of patients without all-cause discontinuation over the treatment course in the SSRI and Moclobemide groupsSSRI: Selective Serotonin Reuptake Inhibitor.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3285744&req=5

Figure 1: Proportion of patients without all-cause discontinuation over the treatment course in the SSRI and Moclobemide groupsSSRI: Selective Serotonin Reuptake Inhibitor.
Mentions: In order to compare the observed number of all-cause discontinuation with what would be expected between the SSRI and moclobemide groups, the expected number of all-cause discontinuation every 2 weeks after starting medication was calculated under the assumption that each patient's risk of discontinuation would be equal to the risk of the general population. To analyse this risk, life table survival methods were used.28 Life table survival curves were generated to quantify the time to each medication discontinuation or switching, and to compare the survival curves between two medication groups during the total treatment period after starting medications. Differences in survival curves for both groups were compared using the Wilcoxon statistic (Figure 1).

Bottom Line: Overall, all-cause discontinuation rates were significantly lower with SSRIs (81%) than moclobemide (96%, χ²=4.532, p=0.033).The SSRI group had a longer treatment duration and lower all-cause discontinuation rate than moclobemide.Further, only the type of medication had a significant effect on all-cause discontinuation rates and therefore, we could predict better treatment adherence with the SSRIs in the treatment of SAD.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

ABSTRACT

Objective: With respect to the pharmacotherapy of social anxiety disorder (SAD), it has been suggested that treatment duration is an important factor that can significantly predict responses. The present study aimed to compare the treatment adherence of SAD patients who were taking either SSRIs or reversible inhibitors of MAO-A (moclobemide) by measuring treatment duration and all-cause discontinuation rates of pharmacotherapy in a natural clinical setting.

Methods: We retrospectively analysed the data of 172 patients diagnosed with SAD. Depending on their medication, we divided the patients into two groups, SSRI (n=54) or moclobemide (n=118). The expected number of all-cause discontinuation every 2 weeks after starting treatment was calculated by life table survival methods. A multi-variable Cox proportional hazard regression was used to analyze the potential influence of explanatory variables.

Results: Treatment duration was significantly longer in the SSRI group [46.41±56.96, median=12.0 (weeks)] than in the moclobemide group [25.53±34.74, median=12.0 (weeks), Z=2.352, p=0.019]. Overall, all-cause discontinuation rates were significantly lower with SSRIs (81%) than moclobemide (96%, χ²=4.532, p=0.033).

Conclusion: The SSRI group had a longer treatment duration and lower all-cause discontinuation rate than moclobemide. Further, only the type of medication had a significant effect on all-cause discontinuation rates and therefore, we could predict better treatment adherence with the SSRIs in the treatment of SAD.

No MeSH data available.


Related in: MedlinePlus